



US 20090004179A1

(19) **United States**(12) **Patent Application Publication****Ravetch et al.**(10) **Pub. No.: US 2009/0004179 A1**(43) **Pub. Date: Jan. 1, 2009**

(54) **POLYPEPTIDES WITH ENHANCED
ANTI-INFLAMMATORY AND DECREASED
CYTOTOXIC PROPERTIES AND RELATING
METHODS**

(75) Inventors: **Jeffrey V. Ravetch**, New York, NY
(US); **Falk Nimmerjahn**, Erlangen
(DE); **Yoshikatsu Kaneko**, Niigata
City (JP)

Correspondence Address:
Fox Rothschild, LLP
Virdante Pharmaceuticals
997 Lenox Drive
Lawrenceville, NJ 08648 (US)

(73) Assignee: **THE ROCKEFELLER
UNIVERSITY**, New York, NY
(US)

(21) Appl. No.: **12/013,212**

(22) Filed: **Jan. 11, 2008**

Related U.S. Application Data


- (63) Continuation of application No. 11/957,015, filed on Dec. 14, 2007, which is a continuation-in-part of application No. PCT/US2007/008396, filed on Apr. 3, 2007, Continuation of application No. PCT/US2007/072771, filed on Jul. 3, 2007, which is a continuation of application No. PCT/US2006/041791, filed on Oct. 27, 2006.
- (60) Provisional application No. 60/789,384, filed on Apr. 5, 2006, provisional application No. 60/734,196, filed on Nov. 7, 2005.

Publication Classification

- (51) **Int. Cl.**
A61K 39/395 (2006.01)
C07K 16/00 (2006.01)
C12P 21/02 (2006.01)
A61P 1/00 (2006.01)
- (52) **U.S. Cl.** **424/130.1; 530/387.1; 435/68.1;
530/388.1**

(57) **ABSTRACT**

The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided.






FIG. 1A

3' SIALYLACTOSE




FIG. 1B




FIG. 1C




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 9A

FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B





FIG. 10C

**FIG. 11**




FIG. 12A




FIG. 12B

POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of patent application Ser. No. 11/957,015, filed on Dec. 14, 2007, which claims the benefit of continuation-in-part patent application of PCT Patent Application Number PCT/U.S. Ser. No. 07/08396, filed on Apr. 3, 2007, which claims the benefit of U.S. Provisional Patent Application No. 60/789,384, filed on Apr. 5, 2006, both of which are incorporated herein by reference. This application is also a continuation patent application of PCT Patent Application Number PCT/US07/72771 filed on Jul. 3, 2007, which claims the benefit of PCT/US06/41791, filed on Oct. 27, 2006 which claims the benefit of U.S. Provisional Patent Application No. 60/734,196, filed on Nov. 7, 2005, all of which are also incorporated herein by reference.

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

[0002] The Research leading to the present invention was supported in part, by National Institutes of Health Grant No. AI 034662. Accordingly, the U.S. Government may have certain rights in this invention.

FIELD OF THE INVENTION

[0003] The present invention relates to a novel method for designing therapeutic polypeptides for treatment of inflammatory diseases.

BACKGROUND

[0004] Although cellular receptors for immunoglobulins were first identified nearly 40 years ago, their central role in the immune response was only discovered in the last decade. They are key players in both the afferent and efferent phase of an immune response, setting thresholds for B cell activation and antibody production, regulating the maturation of dendritic cells and coupling the exquisite specificity of the antibody response to effector pathways, such as phagocytosis, antibody dependent cellular cytotoxicity and the recruitment and activation of inflammatory cells. Their central role in linking the humoral immune system to innate effector cells has made them attractive immunotherapeutic targets for either enhancing or restricting the activity of antibodies in vivo.

[0005] The interaction of antibodies and antibody-antigen complexes with cells of the immune system effects a variety of responses, including antibody dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), phagocytosis, inflammatory mediator release, clearance of antigen, and antibody half-life (reviewed in Daron, *Annu Rev Immunol*, 15, 203-234 (1997); Ward and Ghetie, *Therapeutic Immunol*, 2, 77-94 (1995); Ravetch and Kinet, *Annu Rev Immunol*, 9, 457-492 (1991)), each of which is incorporated herein by reference.

[0006] Antibody constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions. Depending on the amino acid sequence of the constant region of their heavy chains, anti-

bodies or immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, and IgG4; IgA1 and IgA2. The heavy chain constant regions that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively. Of the various human immunoglobulin classes, human IgG1 and IgG3 mediate ADCC more effectively than IgG2 and IgG4.

[0007] Papain digestion of antibodies produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. The Fc region is central to the effector functions of antibodies. The crystal structure of the human IgG Fc region has been determined (Deisenhofer, *Biochemistry*, 20, 2361-2370 (1981), which is incorporated herein by reference). In human IgG molecules, the Fc region is generated by papain cleavage N-terminal to Cys, 226.

[0008] IgG has long been appreciated to mediate both pro- and anti-inflammatory activities through interactions mediated by its Fc fragment. Thus, while Fc-Fc γ R interactions are responsible for the pro-inflammatory properties of immune complexes and cytotoxic antibodies, intravenous gamma globulin (IVIG) and its Fc fragments are anti-inflammatory and are widely used to suppress inflammatory diseases. The precise mechanism of such paradoxical properties is unclear but it has been proposed that glycosylation of IgG is crucial for regulation of cytotoxicity and inflammatory potential of IgG.

[0009] IgG contains a single, N-linked glycan at Asn²⁹⁷ in the CH2 domain on each of its two heavy chains. The covalently-linked, complex carbohydrate is composed of a core, biantennary penta-polysaccharide containing N-acetylglucosamine (GlcNAc) and mannose (man). Further modification of the core carbohydrate structure is observed in serum antibodies with the presence of fucose, branching GlcNAc, galactose (gal) and terminal sialic acid (sa) moieties variably found. Over 40 different glycoforms have thus been detected to be covalently attached to this single glycosylation site. Fujii et al., *J. Biol. Chem.* 265, 6009 (1990). Glycosylation of IgG has been shown to be essential for binding to all Fc γ Rs by maintaining an open conformation of the two heavy chains. Jefferis and Lund, *Immune. l Lett.* 82, 57 (2002), Sondermann et al., *J. Mol. Biol.* 309, 737 (2001). This absolute requirement of IgG glycosylation for Fc γ R binding accounts for the inability of deglycosylated IgG antibodies to mediate in vivo triggered inflammatory responses, such as ADCC, phagocytosis and the release of inflammatory mediators. Nimmerjahn and Ravetch, *Immunity* 24, 19 (2006). Further observations that individual glycoforms of IgG may contribute to modulating inflammatory responses has been suggested by the altered affinities for individual Fc γ Rs reported for IgG antibodies containing or lacking fucose and their consequential effects on cytotoxicity. Shields et al., *J. Biol. Chem.* 277, 26733 (2002), Nimmerjahn and Ravetch, *Science* 310, 1510 (2005). A link between autoimmune states and specific glycosylation patterns of IgG antibodies has been observed in patients with rheumatoid arthritis and several autoimmune vasculitides in which decreased galactosylation and sialylation of IgG antibodies have been reported. Parekh et al., *Nature* 316, 452 (1985), Rademacher et al., *Proc. Natl. Acad. Sci. USA* 91, 6123 (1994), Matsumoto et al., 128, 621 (2000), Holland et al., *Biochim. Biophys. Acta* Dec 27; [Epub ahead of print]

2005. Variations in IgG glycoforms have also been reported to be associated with aging and upon immunization, although the in vivo significance of these alterations have not been determined. Shikata et al., *Glycoconj. J.* 15, 683 (1998), Lastre, et al., *Autoimmunity* 28, 25 (1998).

[0010] Accordingly, there is a need for the development of methods for the generation of polypeptides that would account for the disparate observations of IVIG properties in vivo.

SUMMARY OF INVENTION

[0011] The present invention fills the foregoing need by providing such methods and molecules. In one aspect, the invention provides an isolated polypeptide containing at least one IgG Fc region, having altered properties compared to an unpurified antibody preparation, wherein sialylation of the isolated polypeptide is higher than the sialylation of the unpurified antibody preparation. In one embodiment, the isolated polypeptide containing at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody. In one embodiment the isolated polypeptide containing at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a reduced binding to an Fc activating receptor as compared to an unpurified antibody preparation. In a further embodiment the Fc activating receptor is selected from the group consisting of Fc γ RIIA, Fc γ RIIC and Fc γ RIIIA.

[0012] In one aspect, the isolated polypeptide is derived from a recombinant source.

[0013] In another aspect, the instant invention provides a pharmaceutical formulation comprising a polypeptide containing at least one Fc region having a higher anti-inflammatory activity, in combination with a suitable carrier or diluent.

[0014] In another aspect, the invention provides a method of modulating properties of a polypeptide comprising an Fc region comprising altering the sialylation of the polysaccharide chain of the Fc region.

[0015] In one embodiment the method comprises: providing an unpurified source of the polypeptide containing at least one Fc region, said unpurified source of the polypeptide containing at least one Fc region comprising a plurality of the polypeptides containing at least one Fc region having a polysaccharide chain comprising a terminal sialic acid connected to a galactose moiety through a α 2,6 linkage, and a plurality of the polypeptides containing at least one Fc region lacking a polysaccharide chain comprising a terminal sialic acid connected to a galactose moiety through the α 2,6 linkage; and increasing the ratio of the plurality of the polypeptides containing at least one Fc region having the polysaccharide chain comprising the terminal sialic acid connected to the galactose moiety through the α 2,6 linkage to the plurality of the polypeptide containing at least one Fc region lacking the polysaccharide chain comprising the terminal sialic acid connected to the galactose moiety through the α 2,6 linkage.

[0016] In yet another embodiment the invention provides a method of treating an inflammatory disease comprising administering to a subject in need thereof a therapeutic composition comprising a plurality of isolated polypeptides, each containing at least one IgG Fc region, wherein a first portion of the respective Fc regions comprises respective carbohy-

drate chains having galactose moieties connected to respective terminal sialic acid moieties by 2,6 linkage; a dose of the therapeutic composition is smaller than a dose of a second composition which comprises a plurality of isolated polypeptides, each containing at least one IgG Fc region, having a second portion of the respective Fc regions comprising respective carbohydrate chains having galactose moieties connected to respective terminal sialic acid moieties by 2,6 linkage; and either the first portion is greater than the second portion, whereby the dose of the therapeutic composition and the dose of the second composition suppress inflammation to substantially the same extent, or the first portion is greater than the second portion, whereby the therapeutic composition suppresses inflammation to substantially a greater extent than an equal dose of the second composition.

[0017] In another aspect, the invention provides a method for controlling the properties of an Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. In different embodiments, the sialylation of the Fc region is increased or decreased.

[0018] In another aspect, the invention provides methods of treating diseases comprising administering to a patient in need thereof a therapeutically effective amount of a protein comprising Fc region with altered oligosaccharide sialylation. In different embodiments, the sialylation is increased or decreased. The disease may be selected from oncology-related disorders and diseases or conditions associated with inflammation. In different embodiments, the disease or condition is rheumatoid arthritis or inflammatory bowel disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. 1 is an illustration of MALDI-T of analysis of SNA⁺ FC linkages.

[0020] FIG. 2 summarizes experiments demonstrating that enrichment of α 2,6 linkages between sialic acid and galactose improves anti-inflammatory properties of IVIG Fc fragments.

[0021] FIG. 3 summarizes experiments demonstrating that removal of α 2,6 linkages between sialic acid and galactose attenuates anti-inflammatory properties of IVIG Fc fragments.

[0022] FIG. 4 demonstrates that reduced cytotoxicity does not depend on the linkage between galactose and sialic acid.

[0023] FIG. 5 demonstrates that the in vivo anti-inflammatory activity of the 2,6 sialylated IgG Fc is solely a property of the IgG Fc glycan.

[0024] FIG. 6 illustrates the hierarchy of antibody-isotype mediated effector functions in vivo. Shown are the B16-F10 lung metastasis and platelet depletion models in C57BL/6 mice (mean $\pm$ SEM). (A and B) Mice were injected with B16-F10 melanoma cells followed by injection of TA99-isotype switch variants or control antibodies (200 μ g per injection) on days 0, 2, 4, 7, 9 and 11. Mice were sacrificed 15 days after tumor cell injection and the number of surface lung metastasis was evaluated. Asterisk indicates $P < 0.0001$; double asterisks $P < 0.01$. (C and D) Mice were injected with 4 μ g of 6A6-antibody switch variants and platelet counts were determined at the indicated time points (C). (D) The platelet count 4 hours after injection of the 6A6 isotype variants is shown as the percentage of the total platelet count before antibody injection.

[0025] FIG. 7 illustrates that IgG2a-mediated effects are independent of the complement cascade in vivo (mean $\pm$ SEM). (A) Mice deficient for complement receptor 2

(CR2^{-/-}) or complement component C3 or C4 (C4^{-/-}) were injected with B16-F10 melanoma cells and treated with 100 µg of the TA99-IgG2a antibody per injection. After 15 days animals were sacrificed and lung surface metastasis count was determined. Asterisk indicates $P < 0.0001$. B) C57BL/6, γ -chain^{-/-}, CR2^{-/-}, and C4^{-/-} mice were injected with 4 µg of the 6A6-IgG1, -IgG2a, or IgG2b antibody isotypes and platelet counts were determined before and 4 hours after antibody injection (Nimmerjahn, et al., (2005)). Shown is the platelet count 4 hours after antibody injection relative to the platelet count before injection percent. The experiments were done twice with 3-4 animals per group.

[0026] FIG. 8 illustrates the Fc γ receptor dependence of antibody isotype-mediated effector functions (A and B). Mice deficient for the common γ -chain (γ ^{-/-}), or α (chains of activation Fc γ -receptor I (Fc γ RI^{-/-}) or III (Fc γ RIII^{-/-}) were injected with B16-F10 melanoma cells and treated with 100 µg of the TA99-IgG2a antibody or PBS (mock) as described. At day 15 after tumor cell injection mice were sacrificed, lungs were prepared (A) and the number of lung surface metastasis was quantified (B) (mean $\pm$ SEM). Asterisk indicates $P < 0.0001$. The experiment was performed twice with 5 mice per group. (C and D) Fc γ RI^{-/-} mice were injected with B16-F10 melanoma cells and treated with the TA99-IgG2a antibody at 100 µg per injection. At days 0, 2 and 4 after tumor cell injections mice were injected with 200 µg of an Fc γ RIV blocking antibody or an isotype matched control antibody. Lungs were prepared at day 15 after tumor cell injection (C) and lung surface metastasis was quantified (D) (mean $\pm$ SEM). Asterisk indicates $P < 0.001$. (E) The indicated mouse strains were injected with 4 µg of the 6A6-isotype switch variants and the platelet count was determined 4 hours after injection of the respective antibody variants (mean $\pm$ SEM). To block immune complex binding to Fc γ RIV mice were injected with 200 µg of an Fc γ RIV-blocking antibody (Nimmerjahn, F., et al., (2005)). Shown is the relative platelet count 4 hours after antibody injection in percent. Experiments were performed twice with 4-6 mice per group.

[0027] FIG. 9 illustrates differential isotype specific negative regulation by the inhibitory receptor Fc γ RIIB (A and B). C57BL/6 wild-type or Fc γ -receptor IIB deficient (Fc γ RIIB^{-/-}) mice were injected with B16-F10 melanoma cells and treated with TA99-IgG1 or IgG2a isotype switch variants (100 µg per injection). Lungs were prepared on day 15 after tumor cell injection. The experiment was done twice with 5 mice per group; representative lungs are shown in (A) and the quantification in (B). Asterisk indicates $P < 0.0001$; double asterisk indicates $P < 0.005$. (C) C57BL/6 or Fc γ RIIB^{-/-} mice were injected with 2 µg of the indicated 6A6-antibody isotype variants and platelet counts were determined before and 4 hours after antibody injection. Shown is the increase in platelet depletion for the different antibody isotypes in Fc γ RIIB^{-/-} mice compared to wildtype animals. Shown is one representative out of three experiments with 5 mice per group.

[0028] FIG. 10 illustrates that the enhancement of the (A/I) ratio of modified antibodies increases their efficacy. (A) Shown is the fold increase in association constants (K_A) for the complement component C1q and Fc γ R-receptors I-IV in binding to fucose-containing TA99-IgG1, -IgG2a and -IgG2b isotypes compared to fucose-deficient TA99 isotype switch variants. (B and C) C57BL/6 mice were injected with B16-F10 melanoma cells and treated with TA99-IgG2b containing fucose or TA99-IgG2b deficient in fucose; Shields, R. L., et

al., *J Biol Chem* 277, 26733-40 (2002); Shinkawa, T., et al., *J Biol Chem* 278, 3466-73. (2003); and Niwa R., et al., *Cancer Res* 64, 2127-33. (2004)) (50 µg per injection). Lungs were prepared at day 15 after tumor cell injection. One representative lung out of 4 animals per group (B) and the quantification of the lung surface metastasis count is shown (C). Asterisk indicates $P < 0.0001$.

[0029] FIG. 11 illustrates the effect of reducing sialic acid content on the in vivo cytotoxicity of an antibody. The effect of sialic acid residues in Asn-297 linked sugar side chains on antibody dependent cytotoxicity in vivo is described. Mice (n=4) were injected intravenously with 4 µg of the respective 6A6-IgG1 antibodies and platelet counts were determined before and 4 hours after antibody injection. Shown is the platelet depletion in percent 4 hours after injection of the antibody variants. Abbreviations: SA, sialic acid

[0030] FIG. 12 illustrates factors that influence Fc-receptor dependent activities of antibody isotypes. FIG. 12A indicates individual antibody isotypes have different affinities for activating and inhibitory Fc receptors (see text). Red arrows indicate preferential interactions of the indicated antibody isotypes with cellular Fc-receptors; black arrows indicate lower affinity interactions. In the case of IgG2a the broken red arrow indicates that the interaction might be blocked as Fc γ RI is continuously occupied with monomeric IgG2a. The table summarizes the actual A/I ratios based on the affinities of the individual Fc-receptors for the respective antibody isotypes (Nimmerjahn et al., 2005). FIG. 12B indicates the ratio of activating to inhibitory Fc-receptors on immune cells such as DCs, macrophages and neutrophils is regulated by exogenous factors. Cytokines like IL-4, IL-10 or TGF- β upregulate Fc γ RIIB thereby setting high thresholds for cell activation, whereas inflammatory mediators downregulate the inhibitory and upregulate the activating Fc-receptors. For therapeutic approaches Fc γ RIIB mediated inhibition might be circumvented by using Fc γ RIIB-blocking antibodies.

DETAILED DESCRIPTION

[0031] The inventors have surprisingly found that the cytotoxic and anti-inflammatory response of the IgG Fc domain results from the differential sialylation of the Fc-linked core polysaccharide. The cytotoxicity of IgG antibodies is reduced upon sialylation; conversely, the anti-inflammatory activity of IVIG is enhanced. IgG sialylation is shown to be regulated upon the induction of an antigen-specific immune response, thus providing a novel means of switching IgG from an innate, anti-inflammatory molecule in the steady-state, to a adaptive, pro-inflammatory species upon antigenic challenge. The Fc-sialylated IgGs bind to a unique receptor on macrophages that in turn upregulates an inhibitory Fc γ receptor (Fc γ R) thereby protecting against autoantibody-mediated pathology. See, generally, Ravetch and Nimmerjahn, *J. Experim. Medicine* 24(1): 11-15 (2007). The inventors have further surprisingly discovered that the anti-inflammatory response depends on the nature of the linkage between galactose and sialic acid moieties. The observation that the anti-inflammatory activity of IVIG is dependent on a precise glycan structure on the Fc further supports the model that the inventors have previously advanced (Y. Kaneko, F. Nimmerjahn, J. V. Ravetch, *Science* 313, 670 (2006); F. Nimmerjahn, J. V. Ravetch, *J Exp Med* 204, 11 (2007)) that a specific lectin receptor, and not a canonical Fc receptor, is involved in this pathway. The data underlying this invention support a model in which binding of the 2,6 sialylated Fc to its cognate lectin

receptor expressed on a population of regulatory myeloid cells results in the trans upregulation of the inhibitory IgG Fc on effector macrophages, located at sites of inflammation, such as the inflamed joint, thus raising the threshold required for cytotoxic IgGs to engage activation FcRs and trigger inflammatory responses (F. Nimmerjahn, J. V. Ravetch, *Science* 310, 1510 (2005)).

[0032] Accordingly, the instant disclosure provides an advantageous strategy of creating and selecting IgGs with desired cytotoxic and anti-inflammatory potential.

DEFINITIONS

[0033] Throughout the present specification and claims, the numbering of the residues in an immunoglobulin heavy chain is that of the EU index as in Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), which is expressly incorporated herein by reference. The “EU index as in Kabat” refers to the residue numbering of the human IgG1 EU antibody.

[0034] The term “native” or “parent” refers to an unmodified polypeptide comprising an Fc amino acid sequence. The parent polypeptide may comprise a native sequence Fc region or an Fc region with pre-existing amino acid sequence modifications (such as additions, deletions and/or substitutions).

[0035] The term “polypeptide” refers to any fragment of a protein containing at least one IgG Fc region and fragments thereof, including, without limitation, fully functional proteins, such as, for example, antibodies, e.g., IgG antibodies. When a polypeptide of the invention is compared to an unpurified antibody preparation, such a preparation is typically a blood sample, serum sample, and/or IVIG sample, derived from a mammal, e.g., a human donor. The preparation may be unfractionated or partially fractionated but typically comprises only about 2-4% sialylated Fc containing proteins. Compositions of the invention enriched or formulated to have immunosuppressive activity typically comprise at least about 5% sialylated Fc containing proteins or more (e.g., 5-10%, 10-30%, 30-50%, 50-100% or ranges or intervals thereof).

[0036] The term “Fc region” is used to define a C-terminal region of an immunoglobulin heavy chain. The “Fc region” may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.

[0037] The “CH2 domain” of a human IgG Fc region (also referred to as “C γ_2 ” domain) usually extends from about amino acid 231 to about amino acid 340. The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It has been speculated that the carbohydrate may provide a substitute for the domain-domain pairing and help stabilize the CH2 domain (Burton, *Mol Immunol*, 22, 161-206 (1985), which is incorporated herein by reference).

[0038] The “CH3 domain” comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e., from about amino acid residue 341 to about amino acid residue 447 of an IgG).

[0039] The term “hinge region” is generally defined as stretching from Glu216 to Pro230 of human IgG1 (Burton (1985)). Hinge regions of other IgG isotypes may be aligned

with the IgG1 sequence by placing the first and last cysteine residues forming inter-heavy chain S—S bonds in the same positions.

[0040] The term “binding domain” refers to the region of a polypeptide that binds to another molecule. In the case of an FcR, the binding domain can comprise a portion of a polypeptide chain thereof (e.g., the a chain thereof) which is responsible for binding an Fc region. One exemplary binding domain is the extracellular domain of an FcR chain.

[0041] A “functional Fc region” possesses at least a partial “effector function” of a native sequence Fc region. Exemplary “effector functions” include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays as herein disclosed, for example. The term also includes Fc fragments provided the fragment contains at least one amino acid residue that is glycosylated or suitable for glycosylation as described herein.

[0042] A “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A “variant Fc region” as appreciated by one of ordinary skill in the art comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one “amino acid modification.” Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g., from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% homology with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and more preferably at least about 90% homology therewith, more preferably at least about 95% homology therewith, even more preferably, at least about 99% homology therewith.

[0043] The term “altered glycosylation” refers to a polypeptide, as defined above, be it native or modified, in which the carbohydrate addition to the heavy chain constant region is manipulated to either increase or decrease specific sugar components. For example, polypeptides, such as, for example, antibodies, prepared in specific cell lines, such as, for example, Lec2 or Lec3, may be deficient in the attachment of sugar moieties such as fucose and sialic acid.

[0044] The terms “Fc receptor” or “FcR” are used to describe a receptor that binds to the Fc region of an antibody. In one embodiment of the invention, FcR is a native sequence human FcR. In another embodiment, FcR, including human FcR, binds an IgG antibody (a gamma receptor) and includes receptors of the Fc γ RI, Fc γ RII, and Fc γ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors. Fc γ RII receptors include Fc γ RIIA (an “activating receptor”) and Fc γ RIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor Fc γ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc γ RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see review in Daron, *Annu Rev Immunol*, 15, 203-234 (1997);

FcRs are reviewed in Ravetch and Kinet, *Annu Rev Immunol*, 9, 457-92 (1991); Capel et al., *Immunomethods*, 4, 25-34 (1994); and de Haas et al., *J Lab Clin Med*, 126, 330-41 (1995), Nimmerjahn and Ravetch 2006, Ravetch Fc Receptors in *Fundamental Immunology*, ed William Paul 5th Ed. each of which is incorporated herein by reference).

[0045] “Antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to an in vitro or in vivo cell-mediated reaction in which cytotoxic cells that express FcRs (e.g., monocytic cells such as natural killer (NK) cells and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. In principle, any effector cell with an activating FcγR can be triggered to mediate ADCC. One such cell, the NK cell, expresses FcγRIII only, whereas monocytes, depending on their state of activation, localization, or differentiation, can express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Ravetch and Bolland, *Annu Rev Immunol*, (2001), which is incorporated herein by reference.

[0046] “Human effector cells” are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least one type of an activating Fc receptor, such as, for example, FcγRIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, and neutrophils, with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source thereof, e.g., from blood or PBMCs as described herein.

[0047] The term “antibody” is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multi-specific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.

[0048] The phrase “sialic acid content” of an antibody refers both to the total number of sialic acid residues on an Fc region of a heavy chain of an antibody and to the ratio of sialylated antibodies to asialylated antibodies in an unpurified antibody preparation, unless the phrase is in a context clearly suggesting that another meaning is intended.

[0049] “Antibody fragments”, as defined for the purpose of the present invention, comprise a portion of an intact antibody, generally including the antigen binding or variable region of the intact antibody or the Fc region of an antibody which retains FcR binding capability. Examples of antibody fragments include linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The antibody fragments preferably retain at least part of the hinge and optionally the CH1 region of an IgG heavy chain. More preferably, the antibody fragments retain the entire constant region of an IgG heavy chain, and include an IgG light chain.

[0050] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The

modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler and Milstein, *Nature*, 256, 495-497 (1975), which is incorporated herein by reference, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567, which is incorporated herein by reference). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al., *Nature*, 352, 624-628 (1991) and Marks et al., *J Mol Biol*, 222, 581-597 (1991), for example, each of which is incorporated herein by reference.

[0051] In other embodiments of the invention, the polypeptide containing at least one IgG Fc region may be fused with other protein fragments, including, without limitation, whole proteins. A person of ordinary skill in the art will undoubtedly appreciate that many proteins may be fused with the polypeptide of the present invention, including, without limitation, other immunoglobulins, especially, immunoglobulins lacking their respective Fc regions. Alternatively, other biologically active proteins or fragments thereof may be fused with the polypeptide of the present invention, as described, for example, in the U.S. Pat. No. 6,660,843, which is incorporated herein by reference. This embodiment is especially advantageous for delivery of such biologically active proteins or fragments thereof to cells expressing Fc receptors. Further, different markers, such as, for example, GST tag or green fluorescent protein, or GFP, may be used.

[0052] The monoclonal antibodies herein specifically include “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567; Morrison et al., *Proc Natl Acad Sci USA*, 81, 6851-6855 (1984); Neuberger et al., *Nature*, 312, 604-608 (1984); Takeda et al., *Nature*, 314, 452-454 (1985); International Patent Application No. PCT/GB85/00392, each of which is incorporated herein by reference).

[0053] “Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of

the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., *Nature*, 321, 522-525 (1986); Riechmann et al., *Nature*, 332, 323-329 (1988); Presta, *Curr Op Struct Biol*, 2, 593-596 (1992); U.S. Pat. No. 5,225,539, each of which is incorporated herein by reference.

[0054] The polypeptides of the instant invention may be recombinantly produced, for example, from a cDNA, such as, for example SEQ ID NO: 1. The polypeptides of different embodiments include Fc regions or functional fragments thereof.

[0055] The polypeptides containing at least one IgG Fc region include those in which specific amino acid substitutions, additions or deletions are introduced into a parental sequence through the use of recombinant DNA techniques to modify the genes encoding the heavy chain constant region. The introduction of these modifications follows well-established techniques of molecular biology, as described in manuals such as Molecular Cloning (Sambrook and Russel, (2001)). In addition, the polypeptides with at least one Fc region will include those polypeptides which have been selected to contain specific carbohydrate modifications, obtained either by expression in cell lines known for their glycosylation specificity (Stanley P., et al., *Glycobiology*, 6, 695-9 (1996); Weikert S., et al., *Nature Biotechnology*, 17, 1116-1121 (1999); Andresen D C and Krummen L., *Current Opinion in Biotechnology*, 13, 117-123 (2002)) or by enrichment or depletion on specific lectins or by enzymatic treatment (Hirabayashi et al., *J Chromatogr B Analyt Technol Biomed Life Sci*, 771, 67-87 (2002); Robertson and Kennedy, *Bioseparation*, 6, 1-15 (1996)). It is known in the art that quality and extent of antibody glycosylation will differ depending on the cell type and culture condition employed. (For example, Patel et al., *Biochem J*, 285, 839-845 (1992)) have reported that the content of sialic acid in antibody linked sugar side chains differs significantly if antibodies were produced as ascites or in serum-free or serum containing culture media. Moreover, Kunkel et al., *Biotechnol Prog*, 16, 462-470 (2000) have shown that the use of different bioreactors for cell growth and the amount of dissolved oxygen in the medium influenced the amount of galactose and sialic acid in antibody linked sugar moieties. These studies, however, did not address how varying levels of sialic acid residues influence antibody activity in vivo.

Host Expression Systems

[0056] The polypeptide of the present invention can be expressed in a host expression systems, i.e., host cells, capable of N-linked glycosylation. Typically, such host expression systems may comprise bacterial, fungal, plant, vertebrate or invertebrate expression systems. In one embodiment the host cell is a mammalian cell, such as a Chinese hamster ovary (CHO) cell line, (e.g. CHO-KL; ATCC CCL-61), Green Monkey cell line (COS) (e.g. COS 1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse cell (e.g. NS/O), Baby Hamster Kidney (BHK) cell line (e.g. ATCC CRL-1632 or ATCC CCL-10), or human cell (e.g. HEK 293 (ATCC CRL-1573) or 293T (ATCC CRL-11268)), or any other suitable cell line, e.g., available from public depositories such as the American Type Culture Collection, Rockville,

Md. Further, an insect cell line, such as a Lepidoptera cell line, e.g. Sf9, a plant cell line, a fungal cell line, e.g., yeast such as, for example, *Saccharomyces cerevisiae*, *Pichia pastoris*, *Hansenula* spp., or a bacterial expression system based on *Bacillus*, such as *B. subtilis*, or *Escherichia coli* can be used. It will be appreciated by one of ordinary skill in the art that in some cases modifications to host cells may be required to insure that N-linked glycosylation and glycan maturation occur to result in a complex, biantennary sugar as typically found on the Fc domain of human IgG.

Therapeutic Formulations

[0057] Therapeutic formulations comprising the polypeptides containing at least one IgG Fc region can be prepared for storage by mixing the polypeptides of the present invention having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (see, e.g., Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenyl, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONIC™ or polyethylene glycol (PEG).

[0058] The formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

[0059] The active ingredients may also be entrapped in a microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0060] In preferred embodiments, the formulations to be used for in vivo administration are sterile. The formulations of the instant invention can be easily sterilized, for example, by filtration through sterile filtration membranes.

[0061] Sustained-release preparations may also be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the modified antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule.

Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (see, e.g., U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ -ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C., resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S—S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Creation of Sialylated Polypeptides Containing at Least One IgG Fc Region.

[0062] The polypeptides of the present invention can be further purified or modified so that they have an increased amount of sialic acid compared to unmodified and/or unpurified antibodies. Multiple methods exist to reach this objective. In one method, the source of unpurified polypeptides, such as, for example, IVIG, is passed through the column having lectin, which is known to bind sialic acid. A person of the ordinary skill in the art will appreciate that different lectins display different affinities for α 2,6 versus α 2,3 linkages between galactose and sialic acid. Thus, selecting a specific lectin will allow enrichment of antibodies with the desired type of linkage between the sialic acid and the galactose. In one embodiment, the lectin is isolated from *Sambucus nigra*. A person of the ordinary skill in the art will appreciate that the *Sambucus nigra* agglutinin (SNA) is specific for sialic acids linked to galactose or N-acetylgalactosamine by α (2-6) linkages. Shibuya et al, *J. Biol. Chem.*, 262: 1596-1601 (1987). In contrast, the *Maackia amurensis* ("MAA") lectin binds to sialic acid linked to galactose by α (2-3) linkages. Wang et al, *J Biol. Chem.*, 263: 4576-4585 (1988).

[0063] Thus, a fraction of the polypeptides containing at least one IgG Fc region having a desired linkage between the galactose and the sialic acid will be retained in the column while a fraction lacking such linkage will pass through. The sialylated fraction of the polypeptides containing at least one IgG Fc region can be eluted by another wash with a different stringency conditions. Thus, it is possible to obtain a preparation of the polypeptide of the present invention wherein the content of sialic acid is increased compared to the normal content. Further, one may employ an enzymatic reaction with a sialyltransferase and a donor of sialic acid as described, for example, in the U.S. Pat. No. 2,006,0030521.

[0064] Suitable non-limiting examples of sialyltransferase enzymes useful in the claimed methods are ST3Gal III, which is also referred to as α -(2,3)sialyltransferase (EC 2.4.99.6), and α -(2,6)sialyltransferase (EC 2.4.99.1).

[0065] Alpha-(2,3)sialyltransferase catalyzes the transfer of sialic acid to the Gal of a Gal- β -1,3GlcNAc or Gal- β -1,

4GlcNAc glycoside (see, e.g., Wen et al., *J. Biol. Chem.* 267: 21011 (1992); Van den Eijnden et al., *J. Biol. Chem.* 256: 3159 (1991)) and is responsible for sialylation of asparagine-linked oligosaccharides in glycopeptides. The sialic acid is linked to a Gal with the formation of an α -linkage between the two saccharides. Bonding (linkage) between the saccharides is between the 2-position of NeuAc and the 3-position of Gal. This particular enzyme can be isolated from rat liver (Weinstein et al., *J. Biol. Chem.* 257: 13845 (1982)); the human cDNA (Sasaki et al. (1993) *J. Biol. Chem.* 268: 22782-22787; Kitagawa & Paulson (1994) *J. Biol. Chem.* 269: 1394-1401) and genomic (Kitagawa et al. (1996) *J. Biol. Chem.* 271: 931-938) DNA sequences are known, facilitating production of this enzyme by recombinant expression.

[0066] Activity of α -(2,6)sialyltransferase results in 6-sialylated oligosaccharides, including 6-sialylated galactose. The name " α -(2,6)sialyltransferase" refers to the family of sialyltransferases attaching sialic acid to the sixth atom of the acceptor polysaccharide. Different forms of α -(2,6)sialyltransferase can be isolated from different tissues. For example, one specific form of this enzyme, ST6Gal II, can be isolated from brain and fetal tissues. Krzewinski-Recchi et al., *Eur. J. Biochem.* 270, 950 (2003).

[0067] In addition, a person of average skill in the art will appreciate that cell culture conditions can be manipulated to change the sialylation rate. For example, to increase the sialic acid content, production rate is decreased and osmolality is generally maintained within a lower margin suitable for the particular host cell being cultured. Osmolality in the range from about 250 mOsm to about 450 mOsm is appropriate for increased sialic acid content. This and other suitable cell culture conditions are described in, e.g., U.S. Pat. No. 6,656, 466. Patel et al., *Biochem J.* 285, 839-845 (1992) have reported that the content of sialic acid in antibody linked sugar side chains differs significantly if antibodies were produced as ascites or in serum-free or serum containing culture media. Moreover, Kunkel et al., *Biotechnol. Prog.*, 16, 462-470 (2000) have shown that the use of different bioreactors for cell growth and the amount of dissolved oxygen in the medium influenced the amount of galactose and sialic acid in antibody linked sugar moieties.

[0068] In another embodiment, host cells, such as, for example, immortalized human embryonic retina cells, may be modified by introducing a nucleic acid encoding a sialyltransferase such as, for example, an α -2,3-sialyltransferase or an α -2,6-sialyltransferase, operably linked to a promoter, such as, for example, a CMV promoter. The α -2,3-sialyltransferase may be the human α -2,3-sialyltransferase, known as SIAT4C or STZ (GenBank accession number L23767), and described, for example, in the U.S. Pat. No. 2,005,0181359.

[0069] The nucleic acid encoding the sialyltransferase may be introduced into the host cell by any method known to a person of ordinary skill in the art. Suitable methods of introducing exogenous nucleic acid sequences are also described in Sambrook and Russel, *Molecular Cloning: A Laboratory Manual* (3rd Edition), Cold Spring Harbor Press, NY, 2000. These methods include, without limitation, physical transfer techniques, such as, for example, microinjection or electroporation; transfections, such as, for example, calcium phosphate transfections; membrane fusion transfer, using, for example, liposomes; and viral transfer, such as, for example, the transfer using DNA or retroviral vectors.

[0070] The polypeptide containing at least one IgG Fc region may be recovered from the culture supernatant and can be subjected to one or more purification steps, such as, for example, ion-exchange or affinity chromatography, if desired. Suitable methods of purification will be apparent to a person of ordinary skill in the art.

[0071] A person of ordinary skill in the art will appreciate that different combinations of sialylation methods, disclosed above, can lead to production of the polypeptides containing at least one IgG Fc region with an extremely high level of sialylation. For example, one can express the polypeptide containing at least one IgG Fc region in the host cells over-expressing sialyltransferase, as described above, and then further enrich the sialylated fraction of these polypeptides by, for example, sialylating these polypeptides in an enzymatic reaction followed by an affinity chromatography using lectin-containing columns. Similarly, an enzymatic reaction followed by affinity chromatography may be used for IVIG source of the polypeptides containing at least one IgG Fc region.

[0072] To examine the extent of glycosylation on the polypeptides containing at least one IgG Fc region, these polypeptides can be purified and analyzed in SDS-PAGE under reducing conditions. The glycosylation can be determined by reacting the isolated polypeptides with specific lectins, or, alternatively as would be appreciated by one of ordinary skill in the art, one can use HPLC followed by mass spectrometry to identify the glycoforms. (Wormald, M R et al., *Biochem* 36:1370 (1997).

[0073] To describe the instant invention in more details, several non-limiting illustrative examples are given below.

EXAMPLES

Example 1

IVIG with Increased Sialic Acid Content Exhibits Decreased Cytotoxicity

[0074] To determine if specific glycoforms of IgG are involved in modulating the effector functions of antibodies the role of specific, Asn²⁹⁷-linked carbohydrates in mediating the cytotoxicity of defined IgG monoclonal antibodies was explored. The anti-platelet antibodies, derived from the 6A6 hybridoma, expressed as either an IgG1, 2a or 2b switch variant in 293 cells as previously described (6), were analyzed by mass spectroscopy to determine their specific carbohydrate composition and structure. These antibodies contain minimal sialic acid residues. Enrichment of the sialic acid containing species by *Sambucus nigra* lectin affinity chromatography yielded antibodies enriched 60-80 fold in sialic acid content. Comparison of the ability of sialylated and asialylated 6A6-IgG1 and 2b antibodies to mediate platelet clearance revealed an inverse correlation between sialylation and in vivo activity. Sialylation of 6A6 IgG antibodies resulted in a 40-80% reduction in biological activity.

[0075] To determine the mechanism of this reduction in activity surface plasmon resonance binding was performed on these antibodies for each of the mouse FcYRs and to its cognate antigen.

[0076] Surface plasmon resonance analysis was performed as described in Nimmerjahn and Ravetch, *Science* 310, 1510 (2005). Briefly, 6A6 antibody variants containing high or low levels of sialic acid residues in their sugar side chains were immobilized on the surface of CM5 sensor chips. Soluble Fcγ-receptors were injected at different concentrations

through flow cells at room temperature in HBS-EP running buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% surfactant P20) at a flow rate of 30 μl/min. Soluble Fc-receptors were injected for 3 minutes and dissociation of bound molecules was observed for 7 minutes. Background binding to control flow cells was subtracted automatically. Control experiments were performed to exclude mass transport limitations. Affinity constants were derived from sensorgram data using simultaneous fitting to the association and dissociation phases and global fitting to all curves in the set. A 1:1 Langmuir binding model closely fitted the observed sensorgram data and was used in all experiments.

[0077] A 5-10 fold reduction in binding affinity was observed for the sialylated forms of these antibodies to their respective activating FcγRs as compared to their asialylated counterparts, while no differences in binding affinity for the antigen were observed. Since IgG2b binds with a higher affinity to its activation receptor, FcγRIV, when compared to IgG1 binding to its activation receptor FcγRIII, the effect of sialylation was to generate a binding affinity for IgG2b for its activation receptor FcγRIV that was comparable to that of asialylated IgG1 binding to its activation receptor FcγRIII. This effect of this quantitative difference in activation receptor binding resulted in sialylated IgG2b displaying an in vivo activity comparable to that of asialylated IgG1. Similarly, sialylation of IgG1 reduces its already low binding affinity for its activation receptor FcγRIII by a factor of 7 thereby generating a physiologically inactive antibody. Thus, sialylation of the Asn²⁹⁷ linked glycan structure of IgG resulted in reduced binding affinities to the subclass-restricted activation FcγRs and thus reduced their in vivo cytotoxicity.

[0078] To determine the generality of the observation that sialylation of the N-linked glycan of IgG was involved in modulating its in vivo inflammatory activity, we next examined the role of N-linked glycans on the anti-inflammatory activity of IVIG. This purified IgG fraction obtained from the pooled serum of 5-10,000 donors, when administered intravenously at high doses (1-2 g/kg), is a widely used therapeutic for the treatment of inflammatory diseases. Dwyer, *N. Engl. J. Med.* 326, 107 (1992). This anti-inflammatory activity is a property of the Fc fragment and is protective in murine models of ITP, RA and nephrotoxic nephritis. Imbach et al., *Lancet* 1, 1228 (1981), Samuelsson et al., *Science* 291, 484 (2001), Bruhns et al., *Immunity* 18, 573 (2003), Kaneko et al., *J. Exp. Med.* 203(3):789-97 (2006).

[0079] A common mechanism for this anti-inflammatory activity was proposed involving the induction of surface expression of the inhibitory FcγRIIB molecule on effector macrophages, thereby raising the threshold required for cytotoxic IgG antibodies or immune complexes to induce effector cell responses by activation FcγR triggering. Nimmerjahn and Ravetch, *Immunity* 24, 19 (2006).

Example 2

Asialylation of IVIG Decreases the Anti-Inflammatory Effect of IVIG in Mouse Arthritis Model

[0080] Mice

[0081] C57BL/6 and NOD mice were purchased from the Jackson Laboratory (Bar Harbor, Me.). FcγRIIB^{-/-} mice were generated in the inventors' laboratory and backcrossed for 12 generations to the C57BL/6 background. KRN TCR transgenic mice on a C57BU6 background (K/B) were gifts

from D. Mathis and C. Benoist (Harvard Medical School, Boston, Mass.) and were bred to NOD mice to generate K/B $\times$ N mice. Female mice at 6-10 weeks of age were used for all experiments and maintained at the Rockefeller University animal facility.

[0082] Serum was prepared as described previously (Brühns, et al., *Immunity* 18, 573 (2003)). Briefly, serum is separated from blood collected from the K/B $\times$ N mice (6-12 weeks old). Several weeks of serum collection were pooled together and frozen in aliquots to be used in all the experiments described here. One intravenous injection of 1.5 $\times$ diluted K/B $\times$ N serum (4 μ l of pooled K/B $\times$ N serum per gram of mouse) induced arthritis. Arthritis was scored by clinical examination. Indices of all four paws are added: 0 [unaffected], 1 [swelling of one joint], 2 [swelling of more than one joint], and 3 [severe swelling of the entire paw]. IVIG is injected 1 hr before K/B $\times$ N serum injection. Some mice received 5 μ g of platelet depleting 6A6-IgG2b antibody, and platelet counts were determined at 0, 4, and 24 hours post treatment using an Advia 120 haematology system (Bayer). All experiments were done in compliance with federal laws and institutional guidelines and have been approved by the Rockefeller University (New York, N.Y.).

[0083] Antibodies and Soluble Fc Receptors

[0084] 6A6 antibody switch variants were produced by transient transfection of 293T cells followed by purification via protein G as described. Nimmerjahn and Ravetch, *Science* 310, 1510 (2005). Sialic acid rich antibody variants were isolated from these antibody preparations by lectin affinity chromatography with *Sambucus nigra* agglutinin (SNA) agarose (Vector Laboratories, Burlingame, Calif.). Enrichment for sialic acid content was verified by lectin blotting (see below). Human intravenous immune globulin (IVIG, 5% in 10% maltose, chromatography purified) was purchased from Octapharma (Hemdon, Va.). Digestion of human IVIG was performed as described. Kaneko Y. et al., *Exp. Med.* 203(3): 789-97 (2006). Briefly, IVIG was digested by 0.5 mg/ml papain for 1 hr at 37° C., and stopped by the addition of 2.5 mg/ml iodoacetamide. Fab and Fc resulting fragments were separated from non-digested IVIG on a HiPrep 26/60 S-200HR column (GE Healthcare, Piscataway, N.J.), followed by purification of Fc and Fab fragments with a Protein G column (GE Healthcare) and a Protein L column (Pierce, Rockford, Ill.). Fragment purity was checked by immunoblotting using anti-human IgG Fab or Fc-specific antibodies. (Jackson ImmunoResearch, West Grove, Pa.). Purity was judged to be greater than 99%. The F4/80 antibody was from Serotec (Oxford, UK). The Ly 17.2 antibody was from Caltag (Burlingame, Calif.). Sheep anti-glomerular basement membrane (GBM) antiserum (nephrotoxic serum, NTS) was a gift from M. P. Madaio (University of Pennsylvania, Philadelphia, Pa.). Soluble Fc receptors containing a C-terminal hexahistidine tag were generated by transient transfection of 293T cells and purified from cell culture supernatants with Ni-NTA agarose as suggested by the manufacturer (Qiagen).

[0085] IVIG was treated with neuraminidase and the composition and structure of the resulting preparation was analyzed by mass spectroscopy. No detectable sialic acid containing glycans remained after neuraminidase treatment. These IgG preparations were then tested for their ability to protect mice from joint inflammation induced by passive transfer of K $\times$ N serum, an IgG 1 immune complex-mediated inflammatory disease model. De-sialylation with neuraminidase abrogated the protective effect of the IVIG preparation in

the K $\times$ N serum induced arthritis model. This loss of activity was not the result of reduced serum half-life of the asialylated IgG preparations or the result of changes to the monomeric composition or structural integrity of the IgG. Removal of all glycans with PNGase had a similar effect and abrogated the protective effect of IVIG in vivo.

Example 3

IVIG Fraction with Enriched Sialic Acid Content Decreases Inflammation in Mouse Arthritis Model

[0086] Preparation of Ivig with an Increased Content of Sialic Acid

[0087] Since sialic acid appeared to be required for the anti-inflammatory activity of IVIG, the basis for the high dose requirement (1 g/kg) for this anti-inflammatory activity could be the limiting concentration of sialylated IgG in the total IVIG preparation. The IVIG was fractionated on an SNA-lectin affinity column to obtain IgG molecules enriched for sialic acid modified glycan structures.

[0088] These sialic acid enriched fractions were tested for protective effects in the K $\times$ N serum transfer arthritis model as compared to unfractionated IVIG. A 10 fold enhancement in protection was observed for the SNA-binding fraction, such that equivalent protection was obtained at 0.1 g/kg of SNA-enriched IVIG as compared to 1 g/kg of unfractionated IVIG. The serum half-life and IgG subclass distribution of the SNA enriched fraction was equivalent to that of unfractionated IVIG. The effect of sialylation was specific to IgG; sialylated N-linked glycoproteins such as fetuin or transferrin with similar bi-antennary, complex carbohydrate structures had no statistically significant anti-inflammatory activity at equivalent molar concentrations of IgG. Finally, the mechanism of protection of the sialylated IVIG preparation was similar to unfractionated IVIG in that it was dependent on Fc γ RIIB expression and resulted in the increased expression of this inhibitory receptor on effector macrophages.

Example 4

The Increased Anti-Inflammatory Response of IVIG with Increased Sialic Acid Content is Mediated by Sialylation OF THE N-Linked Glycan on the Fc Domain

[0089] Since the polyclonal IgG in IVIG may also contain O and N linked glycans on the light chains or heavy chain variable domains that can be sialylated, we confirmed that the increase in anti-inflammatory activity of the SNA-enriched IgG preparation resulted from increased sialylation of the N-linked glycosylation site on the Fc. Fc fragments were generated from unfractionated and SNA fractionated IVIG and tested for their in vivo activity. As observed for intact IgG, SNA-purified Fc fragments were enhanced for their protective effect in vivo when compared to Fc fragments generated from unfractionated IVIG. In contrast, Fab fragments displayed no anti-inflammatory activity in this in vivo assay. Thus, the high dose requirement for the anti-inflammatory activity of IVIG can be attributed to the minor contributions of sialylated IgG present in the total preparation. Enrichment of these fractions by sialic acid binding lectin chromatography consequently increased the anti-inflammatory activity.

[0090] These results using passive immunization of IgG antibodies indicated that the ability of IgG to switch from a

pro-inflammatory to an anti-inflammatory species is influenced by the degree of sialylation of the N-linked glycan on the Fc domain.

Example 5

Increase of Anti-Inflammatory Activity, Mediated by Sialylation of IgG, occurs during an Active Immune Response

[0091] Murine Model for Goodpasture's Disease

[0092] In this model, mice are first sensitized with sheep IgG together with adjuvant and four days later injected with a sheep anti-mouse glomerular basement membrane preparation (nephrotoxic serum, NTS). Briefly, mice were pre-immunized intraperitoneally with 200 μ g of sheep IgG (Serotec) in CFA, followed by intravenous injection of 2.5 μ l of NTS serum per gram of body weight four days later. Blood was collected from non-treated control mice four days after the anti-GBM anti-serum injection, and serum IgG was purified by Protein G (GE Healthcare, Princeton, N.J.) and sepharose-bound sheep IgG column, generated by covalently coupling sheep IgG on NHS-activated sepharose column (GE Healthcare, Princeton, N.J.), affinity chromatography.

[0093] Pre-sensitization followed by treatment with NTS induces mouse IgG2b anti-sheep IgG antibodies (NTN immunized). Kaneko Y. et al., *Exp. Med.*, 203:789 (2006). Mouse IgG2b antibodies are deposited in the glomerulus together with the NTS antibodies and result in an acute and fulminant inflammatory response by the IgG2b mediated activation of FcyRIV on infiltrating macrophages. In the absence of pre-sensitization inflammation is not observed, indicating that the mouse IgG2b anti-sheep IgG antibodies are the mediators of the inflammatory response.

[0094] To determine if active immunization resulting in pro-inflammatory IgG is associated with a change in sialylation, serum IgG and IgM from preimmune and NTS immunized mice were characterized for sialic acid content by SNA lectin binding. Total IgG sialylation was reduced on average by 40% in immunized mice as compared to the unimmunized controls. The effect was specific for IgG; sialylation of IgM was equivalent pre and post immunization. This difference in sialylation was more pronounced when the sheep specific IgG fraction from mouse serum was analyzed, showing a 50-60% reduction in sialylation compared to preimmune IgG.

[0095] These results were confirmed by MALDI-TOF-MS analysis. Monosaccharide composition analysis was performed by UCSD Glycotechnology Core Resource (San Diego, Calif.). Glycoprotein samples were denatured with SDS and 2-mercaptoethanol, and digested with PNGase F. The released mixed N-glycans were purified by reversed-phase HPLC and solid-phase extraction, and then exposed hydroxyl groups of the N-glycans were methylated. The resulting derivatized saccharides were purified again by reversed-phase HPLC and subject to MALDI-TOF-MS.

[0096] The analysis of the pre and post immunization IgGs confirmed that the changes in the N-glycan structure were specific to the terminal sialic acids moieties. The mouse IgG2b anti-sheep antibodies that were deposited in the glomeruli, previously shown to be responsible for engagement of the FcyRIV bearing, infiltrating macrophages displayed reduced sialic acid content as compared to the pre-immunized controls.

Example 6

Analysis of Linkages between Sialic Acid and Galactose in IVIG

[0097] Sequential Maldi-T of analysis of SNA⁺ (*Sambucus Nigra* Agglutinin) IVIG Fc linkages was performed to

determine the structure of the sialylated IgG Fc fraction that was protective in the ITP, RA and nephrotoxic nephritis models described above. Glycan peaks generated in Maldi-TOF were isolated, further fractionated, and reanalyzed until galactose-sialic acid structures were obtained. The footprint histogram of the enriched galactose-sialic acid structures with in vivo anti-inflammatory activity (FIG. 1A) were compared to histograms from sialic acid linkage standards, α 2-3 sialyllactose (FIG. 1B) and α 2-6 sialyllactose (FIG. 1C). The signature peaks of the standards are identified by arrows, shown by arrows for α 2-3 (FIG. 1B) or α 2-6 (FIGS. 1A and 1C), respectively, and compared to the peaks obtained from the sample.

Example 7

Enrichment of IVIG FC Fragments in α 2,6 Linkages by In Vitro Glycosylation Improves Anti-Inflammatory Properties of IVIG

[0098] As shown in FIG. 2A, glycan Maldi-T of MS analysis of IVIG Fc fragments showed structures ending in no galactose (peak G0), one galactose (peak G1), two galactose (peak G2), or in sialic acid (indicated by a bracket entitled "Terminal sialic acid"). To determine the in vivo activity of 2, 3 or 2,6 sialylated IgG Fc, samples were treated with sialidase, followed by galactose transferase to convert the G0 (no galactose) and G1 (single galactose) to G2 (fully galactosylated) to increase potential sialylation sites. As shown in FIG. 2B hypergalactosylation was verified by comparing relative band intensity ratios of terminal galactose as measured by ECL and coomassie loading controls. In vitro sialylation was performed (FIG. 2C) using either α 2-6 sialyltransferase ("ST6Gal") or α 2-3 sialyltransferase ("ST3Gal") and confirmed by lectin blotting for α 2-6 linkages with SNA (top) or α 2-3 linkages with ECL (middle) and coomassie (bottom). To evaluate the ability of in vitro sialylated Fc to inhibit inflammation (FIG. 2D) mice received either 0.66 mg of α 2-6 sialylated Fcs (black triangles) or 0.66 mg α 2-3 sialylated Fcs (red triangles). 1 hour later, 0.2 ml of K/BxN sera was administered, and the swelling of footpads (clinical score) was monitored over the next seven days. Anti-inflammatory activity was observed for the 2,6 sialylated IgG Fc fragments but not for the 2,3 sialylated molecules. These results are consistent with the data shown above and indicate that a preferential linkage of 2,6 sialic acid-galactose is involved in the anti-inflammatory activity of sialylated IgG.

Example 8

Removal of α 2-6 but not 2,3 Sialic Acid Linkages Abrogates the Immunosuppressive Properties of IVIG

[0099] IVIG was treated with linkage specific sialidases (SAs), and the digestion verified by lectin blotting (FIG. 3A). The top panel shows positive *Sambucus nigra* lectin (SNA) staining for α 2-6 linkages in IVIG (left lane), and α 2-3 SA tx IVIG (center lane), but not in α 2-3,6 SA tx IVIG (right lane). The middle panel is a dot blot for α 2-3 sialic acid linkages (MAL I), displaying positive staining for the fetuin positive control only; 100 μ g protein are loaded per dot. The bottom panel shows coomassie loading control. 10 μ g/lane are shown in the blot and gel. To examine the effect of specific removal of sialic acid moieties, mice were given 1 g/kg of IVIG preparations prior to 200 μ l of K/BxN sera. As shown in

FIG. 3B, footpad swelling was observed in mice administered K/B $\times$ N sera (white circles) over the course of a week, as measured by clinical scoring. IVIG treated mice showed minimal swelling (black triangles), as did mice treated with α 2-3 SA tx IVIG (white triangles), while mice receiving α 2-3,6 SA tx IVIG (squares) were not protected from footpad swelling.

Example 9

Reduced Cytotoxicity does not Depend on the Nature of Linkage between Sialic Acid and Galactose

[0100] The inventors have previously demonstrated that sialylation of the N-linked glycan associated with the Fc domain of IgG resulted in reduced FcR binding, leading to a reduction in the A/I ratio (Kaneko, et al., *Science* 313, 670 (2006)), a value derived from the affinity constants for an IgG Fc binding to individual activating (A) or inhibitory (I) IgG Fc receptors. This ratio has been shown to be predictive of the in vivo cytotoxicity for a specific IgG Fc (F. Nimmerjahn, J. V. Ravetch, *Science* 310, 1510 (2005)). Fc sialylation thus reduced the cytotoxicity of IgG antibodies in the induced thrombocytopenia model as well as in in vitro models of ADCC (Kaneko, et al., *Science* 313, 670 (2006), Scallon, et al., *Mol. Immunol.* 44, 1524 (2007)). The inventors, therefore, set out to determine if this reduction in FcR binding and cytotoxicity was influenced by the sialic acid-galactose linkage. A monoclonal anti-platelet IgG2b antibody previously shown to lead to platelet consumption was sialylated in vitro as described above and tested for in vivo activity. Both terminal 2,3 and 2,6 in vitro sialylated IgG Fc reduced the cytotoxicity of this anti-platelet antibody, 6A6-IgG2b, in an in vivo model of thrombocytopenia (FIG. 4), consistent with previous studies (Kaneko, et al., *Science* 313, 670 (2006), Scallon, et al., *Mol. Immunol.* 44, 1524 (2007)). Thus, the effect of Fc sialylation on the cytotoxicity of an IgG antibody is not dependent on the specificity of the linkage to the penultimate galactose.

[0101] In contrast, the anti-inflammatory activity of the sialylated IgG Fc fragment (a property which the inventors have shown to be independent of the canonical IgG Fc receptors (F. Nimmerjahn, J. V. Ravetch, *Science* 310, 1510 (2005); F. Nimmerjahn, J. V. Ravetch, *J Exp Med* 204, 11 (2007)) displayed a clear preference for the 2,6 sialic acid-galactose linkage, as seen in FIG. 3B.

[0102] These results further support the inventors' previous observations that the anti-inflammatory property of IVIG is mediated through a distinct pathway that does not involve binding to canonical Fc γ Rs, which is in sharp contrast to

previously accepted models (Park-Min et al., *Immunity* 26, 67 (2007); Siragam et al., *Nat Med* 12, 688 (2006)).

Example 10

In Vivo Anti-Inflammatory Activity of the 2,6 Sialylated IGG Fc is solely a Property of the IGG Fc Glycan

[0103] To fully demonstrate that the in vivo anti-inflammatory activity of the 2,6 sialylated IgG Fc is solely a property of the IgG Fc glycan and not the result of other components that might be found in the heterogeneous, IVIG Fc preparations, the anti-inflammatory activity of sialylated IVIG Fc was recapitulated using a homogeneous, recombinant human IgG1 Fc substrate (rFc), derived from a cDNA (SEQ ID NO. 1) expressed in 293T cells. The purified recombinant human IgG1 Fc fragment was glycan engineered in vitro, as described above, by β 1,4 galactosylation, followed by 2,6 sialylation (FIG. 5A). The preparation was purified and characterized by lectin blotting and MALDI-TOF analysis (FIG. 5A) before in vivo analysis. Glycosylation was confirmed by lectin blotting for terminal galactose with ECL (top panel), α 2,6 sialic acid with SNA (middle panel), and coomassie loading controls are shown in the bottom panel.

[0104] Mice were administered IVIG, SNA+ IVIG Fcs, or sialylated rFc (2,6ST rFc) 1 hour prior to K/B $\times$ N sera, and footpad swelling was monitored over the next several days. As seen in FIG. 5B, the 2,6 sialylated recombinant human IgG1 Fc fragment demonstrated comparable anti-inflammatory activity to that obtained with either IVIG-derived sialic-enriched Fc fragments (SNA+ IVIG Fc) or in vitro 2,6 sialylated IVIG-derived Fc fragments (2,6ST IVIG Fc). Mean and standard deviation of clinical scores of 4-5 mice per group are plotted; *denotes $p < 0.05$ as determined by Kruskal-Wallis Anova followed by Dunn's post hoc.

[0105] Each of these preparations was active at 30 mg/kg, as compared to the 1,000-2,000 mg/kg required for native IVIG (Table 1).

TABLE 1

Different dosages of Fc fragment containing preparations result in the same extent of inflammation suppression in arthritis model.							
IVIG prep	IVIG	IVIG Fc	SNA ⁺ IVIG	SNA ⁺ IVIG Fc	2.3ST IVIG Fc	2.6ST IVIG Fc	2.6ST rFc
Dose	1 g/kg	0.33 g/kg	0.1 g/kg	0.033 g/kg	0.033 g/kg	0.033 g/kg	0.033 g/kg
Amount/ mouse injection	20 mg	6.66 mg	2 mg	0.66 mg	0.66 mg	0.66 mg	0.66 mg

Example 11

In Vivo Activity Of IgG Subclasses Dependant On Fc γ R Specificity

[0106] To address the role of individual Fc γ Rs to the in vivo activities of specific IgG subclasses a series of antibodies were constructed for two defined epitopes, in which the V_H regions of the cloned hybridoma recognizing either the melanosome gp75 antigen (TA99 family) or anti-platelet integrin antigen (6A6 family) were grafted onto the C57BL/6-derived G1, 2a, 2b or 3 constant regions and co-expressed with the appropriate light chains in 293 T cells (Nimmerjahn et al.,

Immunity 23, 41-51 (2005); Vijayasaradhi et al., *J. Exp Med* 171, 1375-80 (1990); and Clynes et al., *Proc Natl Acad Sci USA* 95, 652-6 (1998)). These recombinant antibodies were purified and tested for binding affinity to their cognate antigen (Table 2) and to soluble, recombinantly expressed Fc γ R I, II, III or IV by surface plasmon resonance or to transfected cells expressing a heterologous Fc receptor. Switching IgG constant regions did not affect the binding affinity of the resultant antibodies to their respective antigens (Table 2).

TABLE 2

Affinities of TA99-antibody switch variants for gp75		
	KA(1/M)	KD(M)
TA99-IgG1	2.7×10^9 *	3.8×10^{-10}
TA99-IgG2a	1.6×10^9	6.1×10^{-10}
TA99-IgG2b	1.8×10^9	5.7×10^{-10}
TA99-IgG3	1.5×10^9	6.6×10^{-10}

* Antibody affinities were determined by surface plasmon resonance (SPR) analysis (Nimmerjahn et al., (2005)). A soluble version of the extracellular domain of gp75 was injected at a flow rate of 30 μ l/min over the immobilized antibody variants and association and dissociation constants were calculated. Each data point represents the mean of five experiments performed in duplicates at different concentrations with a SE below 5%. Id.

[0107] In contrast, specific differences in binding affinity of each subclass to specific Fc γ Rs were observed, as shown in Table 3. For example, IgG1 bound with 10-fold higher affinity to the inhibitory receptor Fc γ RIIB than to its activation counterpart, Fc γ RIII, while IgG2a and 2b displayed the reverse pattern, binding with 10-fold higher affinity for the activation receptor Fc γ RIV than to the inhibitory receptor Fc γ RIIB. IgG3 did not bind to any of the known Fc γ Rs. The ratio of activation to inhibitory binding (A/I), as shown in Table 2, thus can differ by as much as 2 orders of magnitude between IgG subclasses and FcRs.

TABLE 3

Affinities of Fc γ -receptors for antibody isotypes					
	sFc γ RIIB	sFc γ RIII	sFc γ RIV	sFc γ RI	A/I
IgG1 (+fucose)	3.33×10^6	0.31×10^6	—/—	—/—	0.1
IgG1 (—fucose)	1.32×10^6	0.51×10^6	—/—	—/—	0.4
IgG1 (—SA)	4.00×10^6	0.50×10^6	—/—	—/—	0.1
IgG1 (+SA)	0.39×10^6	0.07×10^6	—/—	—/—	0.2
IgG2a (+fucose)	0.42×10^6	0.68×10^6	2.9×10^7	1.6×10^8	69**
IgG2a (—fucose)	3.34×10^6	1.54×10^6	3.06×10^8	1.8×10^8	92**
IgG2b (+fucose)	2.23×10^6	0.64×10^6	1.7×10^7	—/—	7**
IgG2b (—fucose)	1.0×10^7	1.06×10^6	2.03×10^8	—/—	20**
IgG3	—/—	—/—	—/—	—/—	—/—

*Numbers represent the affinity (K_A) of the indicated antibody isotypes to the indicated soluble Fc γ -receptors (sFc γ R) as measured by surface plasmon resonance analysis (Nimmerjahn et al., (2005)). A/I is the ratio of the affinity of the activating (sFc γ RIII or sFc γ RIV, respectively) to the inhibitory receptor Fc γ RIIB. A double asterisk indicates the ratio of sFc γ RIV to sFc γ RIIB; —/— indicates no detectable binding. Each data point represents the mean of five experiments performed in duplicates at different concentrations with a SE below 5%. +/— SA indicates antibodies enriched or depleted for sialic acid sugar residues. Id.

Materials and Methods:

[0108] Mice: C57BL/6 and C57BL/6-129SF2/J mice were obtained from the Jackson Laboratory (Bar Harbor, Me.). γ ^{—/—} Fc γ RIIB^{—/—} and Fc γ RIII^{—/—} mice were generated in our laboratory and backcrossed for 12 generations to the C57BL/6 background. Fc γ RI^{—/—} 129/B6 mice were generously pro-

vided by Dr. Hogarth (The Austin Research Institute, Victoria, Australia). Fc γ RI/III^{—/—} mice were generated in our laboratory by crossing Fc γ RI^{—/—} with Fc γ RIII^{—/—} mice and subsequent selection for double knockout animals. CR2^{—/—}, C3^{—/—} and C4^{—/—} knockout mice were provided by Michael Carroll (CBR Institute for Biomedical Research, Harvard Medical School). Female mice at 2 to 4 months of age were used for all experiments and maintained at the Rockefeller University animal facility. All experiments were done in compliance with federal laws and institutional guidelines and have been approved by the Rockefeller University (New York, N.Y.).

[0109] Cell culture: 293T, CHO-K1, B16-F10 and YB2/0 cells were cultured according to ATCC guidelines.

[0110] Antibodies and recombinant proteins: The 6A6 and TA99 antibody isotype switch variants and soluble Fc γ -receptors and gp75 were produced by transient transfection of 293T cells and subsequent purification from culture supernatants as described (Nimmerjahn, F., et al., (2005)). For generation of TA99 antibody variants lacking fucose YB2/0 cells were stably transfected with the respective TA99 heavy and light chains. Fucose content of antibodies was verified by immunoblotting with biotinylated aleuria aurantia lectin (Vector laboratories) followed by detection with streptavidin-AP (Roche). Antibodies enriched or depleted for sialic acid residues were generated by affinity chromatography with *sambucus nigra* lectin (Vector laboratories). Sialic acid content was verified by immunoblotting with biotinylated *sambucus nigra* lectin (Vector laboratories). Purified Clq was from Calbiochem. The Fc γ RIV-blocking antibody 9E9 has been described before Id. A hamster IgG1 anti-TNP antibody was used as an isotype control antibody (Pharmingen).

[0111] Surface plasmon resonance (SPR) analysis: A Biacore 3000 biosensor system was used to assay the interaction of soluble mouse Fc γ -receptors I, II, III and IV and soluble gp75 with the indicated antibody isotypes. Additionally, soluble human Fc γ -receptors IIA (131H-allele), IIB and IIIA (158F-allele) were used to measure the affinity to human IgG antibody isotypes. Antibodies or BSA as a control protein were immobilized at high and low densities to flow cells of CM5 sensor chips (Biacore) by standard amine coupling as suggested by the manufacturer. Soluble Fc γ -receptors were injected at 5 different concentrations through flow cells at room temperature in HBS-EP running buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% surfactant P20) at a flow rate of 30 μ l/min. Soluble Fc-receptors were injected for 3 minutes and dissociation of bound molecules was observed for 10 minutes. Background binding to control flow cells was subtracted automatically. Control experiments were performed to exclude mass transport limitations. Affinity constants were derived from sensorgram data using simultaneous fitting to the association and dissociation phases and global fitting to all curves in the set. As described for soluble human Fc-receptors a 1:1 Langmuir binding model closely fitted the observed sensorgram data and was used in all experiments Id. Alternatively, soluble Fc-receptors were immobilized to sensor chips with the same result described above.

[0112] In vivo model systems: The platelet depletion model: Experiments were performed essentially as described before. Id. Briefly, mice were injected intravenously with 4 μ g of the recombinant 6A6 antibody isotype switch-variants diluted in 200 μ l of PBS. Alternatively, mice were injected with 2 μ g of the 6A6 antibody variants to study Fc γ RIIB-

mediated negative regulation of antibody functions in vivo. Platelet counts before injection and at indicated time points after injection were determined by blood collection (40 μ l) from the retro-orbital plexus and measuring platelet counts of a 1:10 dilution in PBS/5% BSA in an Advia 120 haematology system (Bayer). To block Fc γ RIV in vivo mice were injected 30 minutes before administration of the 6A6 antibody variants with 200 μ g of the blocking Fc γ RIV antibody 9E9 or with 200 μ g of a hamster isotype control antibody (Pharmingen).

[0113] The B16-F10 lung metastasis model: Experiments were performed as described (Vijayasaradhi et al., *J Exp Med* 171, 1375-80. (1990); and Clynes et al., *Proc Natl Acad Sci USA* 95, 652-6. (1998)) with minor modifications. Mice were injected with 5×10^5 B16-F10 tumor cells intravenously and either left untreated or were injected with the indicated amounts of isotype control (Sigma) or TA99-isotype switch variants on days 0, 2, 4, 7, 9, 11 intraperitoneally. To block Fc γ RIV in vivo mice were injected with 200 μ g of the 9E9 or the respective hamster isotype control antibody on days 0, 2, and 4 intravenously. On day 15 after tumour cell injection mice were sacrificed and lungs were analyzed for the presence of surface metastasis by an investigator blinded for the experimental setup.

[0114] Statistical analysis: The paired Student's t-test was used for determining significance of the results.

Example 12

A/I Ratios Of Antibody Variants Predictive Of In Vivo Biological Activity

[0115] To determine how these differences in binding affinities relate to in vivo biological activity, the ability of these antibodies to mediate tumor clearance or platelet depletion was investigated. As seen in FIG. 6, both TA99 (FIGS. 6A and B) and 6A6 (FIGS. 6C and D) with IgG2a constant regions display enhanced tumor or platelet clearance, respectively, as compared to these antibodies with IgG1 constant regions. IgG2a and 2b are equivalent in their ability to mediate platelet clearance, while IgG2a results in enhanced tumor ADCC in the metastatic melanoma model as compared to IgG2b. The hierarchy of activity for the IgG subclasses is thus IgG2a>IgG2b>IgG1>IgG3. The mechanism of this differential activity was determined by repeating these experiments in specific activating Fc γ R or complement deficient strains. No differences in in vivo activity were observed for IgG1, 2a or 2b in complement deficient strains (C4, C3 or CR1/2) (FIG. 7). In contrast, IgG1, 2a and 2b were all dependent on activating Fc γ R expression, since activity was abrogated in the common γ chain deficient background (FIGS. 8A, B and E). While IgG2a activity could result from its ability to bind with high affinity to Fc γ RI, intermediate affinity to Fc γ RIV or low affinity to Fc γ R III, only Fc γ RIV binding was relevant to its in vivo activity (FIGS. 8C, D and E). Similarly, IgG2b activity was Fc γ RIV dependent and Fc γ RIII independent (FIG. 8E). In contrast, IgG1 mediated effector activity was exclusively Fc γ RIII dependent (FIG. 8E).

[0116] The balance of activation to inhibitory receptor expression has been shown to determine the threshold for IgG mediated effector cell triggering (Ravetch and Lanier, *Science* 290, 84-9 (2000)). The binding affinities of IgG subclasses to the inhibitory receptor vary by a factor of 10, suggesting that a differential dependence of the subclasses on the inhibitory effect of Fc γ RIIB might be observed. As seen in FIG. 9, IgG1 displays the greatest enhancement in activity in

mice lacking the inhibitory receptor in both the tumor clearance and platelet depletion models (FIG. 9A-C), while IgG2a shows the smallest enhancement in both models. The magnitude of IgG2b enhancement in Fc γ RIIB deficient strains differs in the two models, showing significant enhancement in the tumor clearance model and minimal enhancement in the platelet depletion model. This difference is likely due to the intermediate A/I ratio of this receptor rendering it more sensitive to the levels of surface expression of Fc γ RIIB on the specific effector cells mediating the in vivo responses. Since different populations of effector cells are responsible for the biological responses in the two models, the IgG2b data support our previous observations that RIIB levels are minimal on splenic macrophages, the cell type responsible for platelet clearance (Nimmerjahn et al., *Immunity* 23, 41-51. (2005); and Samuelsson et al., *Science* 291, 484-6. (2001)), and higher on alveolar macrophages, the relevant effector cells in the metastatic melanoma model (Shushakova et al., *J Clin Invest* 110, 1823-30 (2002)). These results demonstrate the predictive value of the A/I ratio in determining the contribution of inhibitory signaling to in vivo activities. A high A/I ratio, as found for IgG2a, renders the antibody essentially insensitive to differences in Fc γ RIIB expression on different effector cell populations, while a low A/I ratio, as found for IgG1, maximizes the role of Fc γ RIIB. For antibodies with intermediate A/I ratios, like IgG2b, the in vivo activity will be determined by the specific effector cell involved in the response, reflecting the differences in Fc γ RIIB levels and its regulation by the cytokine milieu. This difference in Fc γ RIIB dependence for IgG1 and IgG2 may reflect the biological roles of these subclasses in vivo, insuring that the most abundant subclass, IgG1, is under tight regulation by an inhibitory receptor, thus preventing effector cell activation in the absence of a second signal that down regulates Fc γ RIIB and lowers the threshold for activation. Such second signals are provided by pro- and anti-inflammatory cytokines and chemokines which have been demonstrated to alter the levels of surface expression of activation or inhibitory receptors (Shushakova (2002)). In contrast, the role of inhibitory receptor expression on IgG2a potency, and to a lesser extent, IgG2b, is less significant, reflecting the effector bias of T_{H1} cytokines which induce both IgG2a switching and Fc γ RIV expression.

Example 13

Modified Antibody With A Lower Amount Of Fucose And A Greater A/I Ratio Compared To Unmodified Antibody

[0117] The relationship between the A/I ratio of IgG subclasses and in vivo activity was further tested using modified IgG constant regions. FcR binding to IgG is dependent on the presence of N-linked glycosylation at position 297; deglycosylation abrogates all FcR binding (Krapp, *J Mol Biol* 325, 979-89 (2003)). However, selective removal of specific carbohydrates, such as fucose, has been suggested to modify human IgG1 binding to human Fc γ RIII and thus to NK cell mediated ADCC in vitro (Shields, R. L., et al., *J Biol Chem* 277, 26733-40. (2002); T. Shinkawa et al., *J Biol Chem* 278, 3466-73 (2003); and Niwa et al., *Cancer Res* 64, 2127-33 (2004)). Fucose-deficient TA99-IgG1, 2a and 2b were prepared and their binding to Fc γ RI, II, III and IV was compared. Clq or antigen binding was not affected by the lack of fucose as described before (Shields (2002)). However, as shown in

FIG. 10 and Table 3, fucose deficient antibodies differed in their binding affinities to their cognate FcγRs, with TA99-IgG1 with or without fucose displaying minimal differences in binding to FcRIIB and III, while IgG2a and 2b fucose deficient antibodies bound with an order of magnitude higher affinity to FcRIIB and FcRIV as compared to fucose sufficient antibodies. These differences in binding affinities resulted in altered A/I ratios that were most pronounced for IgG2b (FIG. 10 and Table 3) and translated into significantly enhanced in vivo activity for IgG2b. This selective effect of de-fucosylation on FcR binding further illustrates the specificity of IgG subclasses in their interactions with individual FcRs and the predictive value of the A/I ratio in determining in vivo activity.

Example 14

Modified Antibody With A Lower Amount Of Sialic Acid

[0118] The role of sialic acid residues in antibody sugar side chains was investigated by injecting mice with 6A6-IgG1 antibody variants enriched or depleted for sialic acid residues and measuring antibody mediated platelet depletion. Antibodies enriched for sialic acid in their sugar side chains displayed strongly reduced affinity for both the activating FcRIII and inhibitory FcRIIB (Table 3). Consistent with this loss in overall affinity for Fc-receptors and the low A/I ratio of 0.18, this antibody had a severely impaired in vivo activity and mediated only minimal platelet depletion (FIG. 11).

Example 15

Human Antibodies Display Differential A/I Ratios

[0119] To investigate if human antibody isotypes also display differential A/I ratios soluble versions of human Fcγ-receptors were prepared and their affinity for human IgG antibody isotypes was measured by surface plasmon resonance analysis. As shown in Table 4 human FcRs also have differential A/I ratios for individual human IgG antibody isotypes.

TABLE 4

	Affinities of Human FcRs to Human IgG Isotypes			A/I	
	sFcRIIB	sFcRIIA	sFcRIIIA	IIA/IIB	IIIA/IIB
IgG1	7.8×10^4	2.5×10^5	4.3×10^5	3.1	5.5
IgG1-fucose	7.8×10^4	2.4×10^5	6.0×10^6	3.1	76
IgG2	3.0×10^4	1.4×10^5	1.4×10^4	4.5	0.4
IgG2-fucose	2.6×10^4	1.3×10^5	1.4×10^5	5.3	5.7
IgG4	4.8×10^4	3.5×10^4	—/—	0.7	n.a.

* Numbers represent the affinity (K_A) of the indicated antibody isotypes to the indicated soluble Fcγ-receptors (sFcγR) as measured by surface plasmon resonance analysis (Nimmerjahn et al., (2005)). A/I is the ratio of the affinity of the indicated activating to the inhibitory receptor FcγRIIB. —/— indicates no detectable binding; n.a. indicated not applicable. Each data point represents the mean of five experiments performed in duplicates at different concentrations with a SE below 5%.

[0120] In contrast to the single chain inhibitory Fc-receptor, activating FcγRs (with the exception of human FcγRIIA) cannot transmit activating signals in the absence of an accessory chain, the common gamma chain (γ-chain), that carries an ITAM motif required for triggering cell activation. FcγRI, FcγRIII and FcγRIV are dependent on γ-chain expression;

thus deletion of this receptor subunit leads to the functional loss of all activating Fc-receptors and several other non-FcR-related proteins such as PIR-A and NK cell cytotoxicity receptors (Moretta et al., *Annu Rev Immunol* 19, 197-223 (2001); Ravetch, (2003)).

[0121] The only IgG isotype that could consistently be assigned to an individual activating Fc-receptor in vivo was IgG1. The deletion of the low affinity receptor FcγRIII abrogates IgG1 mediated effector functions in various models like arthritis, glomerulonephritis, IgG-dependent anaphylaxis, IgG mediated hemolytic anemia and immunothrombocytopenia (Hazenbos et al., *Immunity* 5, 181-188 (1996); Meyer et al., *Blood* 92, 3997-4002 (1998); Fossati-Jimack et al., *J Exp Med* 191, 1293-1302 (2000); Ji et al., *Immunity* 16, 157-168 (2002); Bruhns et al., *Immunity* 18, 573-581 (2003); Fuji et al., *Kidney Int* 64, 1406-1416 (2003); Nimmerjahn et al., (2005)). Under many circumstances, such as host response to viral or bacterial infections (Coutelier et al., *J Exp Med* 165, 64-69 (1987); Schlageter and Kozel, *Infect Immun* 58, 1914-1918 (1990); Markine-Gorianyoff and Coutelier, *J Virol* 76, 432-435 (2002); Taborda et al., *J Immunol* 170, 3621-3630 (2003)), and antibody-mediated cytotoxicity or antibody-based therapy (Kipps et al., *J Exp Med* 161, 1-17 (1985); Fossati-Jimack et al., *J Exp Med* 191, 1293-1302 (2000); Uchida et al., *J Exp Med* 199, 1659-1669 (2004); Nimmerjahn et al., (2005)) the most potent antibody isotypes are of the IgG2a and IgG2b isotype. Therefore, a thorough understanding of how these isotypes exert their function is essential.

[0122] Considering the isotype specificities of the high affinity FcγRI (binding exclusively IgG2a) and the low affinity FcγRIII (binding IgG1, IgG2a, and IgG2b) (reviewed in Ravetch and Kinet, *Annu Rev Immunol* 9, 457-492 (1991); Hulett and Hogarth, *Adv Immunol* 57, 1-127 (1994)), these two receptors are likely candidates responsible for IgG2a and IgG2b effector functions. Although there is some suggestion that FcγRI and III might participate in a limited fashion in IgG2a-mediated effector responses (Ioan-Facsinay et al., *Immunity* 16, 391-402 (2002); Barnes et al., *Immunity* 16, 379-389, (2002)), the majority of studies concluded that IgG2a and IgG2b triggered effects occur independently of these two receptors, but in a gamma chain dependent manner (Hazenbos et al., *Immunity* 5, 181-188 (1996); Meyer et al., (1998); Fossati-Jimack et al., (2000); Uchida et al., (2004); Nimmerjahn et al., (2005)). Especially in the case of IgG2a these results seem to be surprising as FcγRI shows a high affinity for this isotype (K_A : 10^8 - 10^9 M⁻¹). However, the increased affinity allowed this receptor to bind monomeric IgG2a as efficiently as immune complexes (ICs), indicating that newly generated ICs would be expected to have only limited access to FcγRI (FIG. 12A).

[0123] FcγRIV requires γ chain for its surface expression (Nimmerjahn, (2005)) and, as has been described for other γ-chain dependent Fc-receptors, cross-linking of FcγRIV by immune complexes induces activating signaling pathways leading to sustained calcium flux (reviewed in Ravetch and Bolland, (2001); Nimmerjahn et al., (2005)).

[0124] Even if several activating Fc-receptors with the same isotype specificity are present on the same cell, only those Fc-receptors will be engaged that show the optimal affinity for the respective isotype (FIG. 12A). Therefore, IgG1 immune complexes will only trigger FcγRIII as it is the only activating Fc-receptor that can bind IgG1 (Takai, (1994); Hazenbos et al., (1996); Meyer et al., (1998); Nimmerjahn et

al., (2005)). IgG2a and IgG2b, despite their ability to bind FcγRI (in the case of IgG2a) or FcγRIII (in the case of IgG2a and 2b) will functionally be dependent on FcγRIV, as FcγRI will be occupied by monomeric IgG2a and the low affinity of RIII will not result in productive engagement at normal serum concentration of these isotypes. These same principles also apply for the human system, where it has been shown that human FcγRIIIA has a higher affinity for IgG1 as compared to human FcγRIIA. In addition, the presence of allelic variants which show differential affinities for the specific antibody isotypes further supports this concept (Dijstelbloem et al., *Trends Immunol*, 22, 510-516 (2001)).

[0125] The present invention provides a mechanistic basis for the observed variation in IgG subclass activity in both active and passive vaccination and in the variable pathogenicity of the IgG subclasses in autoimmune conditions. The selective FcγR binding affinities of the IgG subclasses, and not their ability to fix complement, is predictive of the in vivo activity for cytotoxic antibodies in models of tumor clearance, platelet and B cell depletion (Uchida et al., *J Exp Med* 199, 1659-69. (2004); Clynes and Ravetch (1995); Clynes

(1998); Samuelsson (2001)). Similarly, the biological consequences of modifications to IgG antibodies are, in turn, dependent on their effects on specific FcR binding affinities that result in changes to the ratio of activation to inhibitory receptor affinities. These considerations will be significant factors in the design of both antibody-based immunotherapeutics and active vaccination protocols to insure either the selective engineering of IgG Fc domains or induction of IgG subclasses with optimal FcγR activation to inhibitory ratios.

[0126] All patent and non-patent publications cited in this disclosure are incorporated herein in to the extent as if each of those patent and non-patent publications was incorporated herein by reference in its entirety. Further, even though the invention herein has been described with reference to particular examples and embodiments, it is to be understood that these examples and embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1

<210> SEQ ID NO 1

<211> LENGTH: 1398

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

atgggtgaca atgacatcca ctttgccttt ctctccacag gtgtccagtc cgaggtgaag      60
ctggatgaga ctggaggagg cttggtgcaa cctgggaggc ccatgaaact ctctgtgttt      120
gcctctggat tcacttttag tgactactgg atgaactggg tccgccagtc tccagagaaa      180
ggactggagt gggtagcaca aattagaaac aaaccttata attatgaaac atattattca      240
gattctgtga aaggcagatt caccatctca agagatgatt ccaaaagtag tgtctacctg      300
caaatgaaca acttaagagt tgaagacatg ggtatctatt actgtacggg ttcttactat      360
ggtatggact actgggggtca aggaacctca gtcaccgtga gtcagcctc caccaagggc      420
ccatcggtct tccccctggc accctcctcc aagagcacct ctggggggcac agcggccctg      480
ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgctgtggaa ctcaggcgcc      540
ctgaccagcg gcgtgcacac cttccccggt gtcctacagt cctcaggact ctactccctc      600
agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaactgt      660
aatcacaagc ccagcaacac caaggtggac aagagagttg agcccaaac ttgtgacaaa      720
actcacacat gccaccgtg cccagcacct gaactcctgg ggggaccgtc agtcttcctc      780
ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg      840
gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgctg      900
gaggtgcata atgccaagac aaagccggcg gaggagcagt acaacagcac gtaccgtgtg      960
gtcagcgctc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgaag      1020
gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag      1080

```

-continued

ccccgagaac cacaggtgta caccctgccc ccatccccggg atgagctgac caagaaccag	1140
gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt ggagtgggag	1200
agcaatgggc agccggagaa caactacaag accacgcctc cgtgctgga ctccgacggc	1260
tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc	1320
ttctcatgct ccgtgatgca tgaggetctg cacaaccact acacgcagaa gagcctctcc	1380
ctgtctccgg gtaaatga	1398

What is claimed is:

1. A method for controlling the properties of an Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region.

2. The method of claim 1, wherein the sialylation is increased in the Fc region.

3. The method of claim 1, wherein the properties controlled are selected from the group consisting of affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.

4. The method of claim 1, wherein the sialylation is altered from the wild type Fc region by at least one method selected from the group consisting of enzymatic treatment, enzymatic modification of the molecule, genetic manipulation of the molecule, lectin chromatography, affinity chromatography, ion exchange chromatography, and changing the cell line used for expression of the protein.

5. The method of claim 4, wherein the enzymatic treatment comprises treating with sialidase or sialyltransferase.

6. The method of claim 1, wherein the Fc-containing molecule has a binding domain specific for a target, said target being an immobilized target.

7. The method of claim 1, wherein the Fc-containing molecule has a binding domain specific for a target, said target being expressed on the surface of a cell.

8. The method of claim 1, wherein the Fc-containing molecule is an antibody.

9. A method for controlling the properties of an Fc-containing therapeutic protein characterized as having the biantennary oligosaccharide covalently attached to an asparagine residue in the CH₂ immunoglobulin domain of said protein, comprising converting an Fc-containing therapeutic protein not of the G2S2 glycoform into an oligosaccharide being substantially of the G2S2 sialylated glycoform.

10. The method of claim 9, wherein said Fc-containing protein has one or more of the properties selected from the group consisting of reduced affinity for FcγRIIA and FcγRIIIA, reduced activity in NK cell-mediated ADCC assays, enhanced affinity for FcγRI, enhanced ability to activate macrophages, and shorter serum half-life as compared to the same Fc-containing therapeutic protein not of the G2S2 glycoform.

11. The method of claim 9, wherein the converting step comprises at least one of enzymatically engineering a recombinantly expressed monoclonal antibody, using chromatography to enrich particular glycoforms, using sialyltransferases to add sialic acid residues, and changing the cell line used for expression of the protein.

12. The method of claim 11, wherein the chromatography comprises lectin affinity chromatography or ion-exchange chromatography.

13. The method of claim 12, wherein the genetic engineering incorporates glycosyltransferases.

14. A method for controlling the properties of an Fc-containing therapeutic protein characterized as having the biantennary oligosaccharide covalently attached to an asparagine residue in the CH₂ immunoglobulin domain of said protein, comprising converting an Fc-containing therapeutic protein of the G2S2 glycoform into an oligosaccharide being substantially of the G2, G1, or G0 non-sialylated glycoforms.

15. The method of claim 14, wherein said Fc-containing protein has one or more of the properties selected from the group consisting of enhanced affinity for FcγRIIA and FcγRIIIA, enhanced activity in NK cell-mediated ADCC assays, reduced affinity for FcγRI, reduced ability to activate macrophages, and longer serum half-life as compared to the same Fc-containing therapeutic protein substantially of the sialylated G2S2 glycoform.

16. An Fc-containing protein produced or altered by the method of claim 1.

17. An Fc-containing therapeutic protein characterized as having the biantennary oligosaccharide covalently attached to an asparagine residue in the CH₂ immunoglobulin domain of said protein being substantially of the G2S2 sialylated glycoform, wherein said Fc-containing protein has reduced affinity for FcγRIIA and FcγRIIIA, reduced activity in NK cell-mediated ADCC assays, enhanced affinity for FcγR^L, enhanced ability to activate macrophages, and shorter serum half-life compared to a preparation of the same Fc-containing therapeutic protein substantially in the non-sialylated G0, G1, or G2 glycoforms.

18. The protein of claim 17, wherein the target bound by the target binding domain of the protein is an immobilized target.

19. The protein of claim 17, wherein the target bound by the binding domain of the protein is expressed on the surface of a cell.

20. The protein of claim 17, wherein the protein is indicated for the treatment of chronic diseases.

21. The protein of claim 17, wherein the protein comprises a recombinantly expressed monoclonal antibody, the antibody modified enzymatically using sialyltransferases, having particular glycoforms enriched using lectin affinity chromatography, or having sialic acid residues removed using sialidases.

22. The protein of claim 17, wherein the protein is a recombinantly expressed monoclonal antibody purified using one or more of affinity chromatography or ion-exchange chromatography.

23. The protein of claim 22, wherein the affinity chromatography is lectin affinity chromatography.

24. The protein of claim 17, wherein the protein is a monoclonal antibody expressed in a genetically engineered host cell having enhanced levels of sialylated or asialylated monoclonal antibodies.

25. An Fc-containing therapeutic protein characterized as having the biantennary oligosaccharide covalently attached to an asparagine residue in the CH₂ immunoglobulin domain of said protein being substantially in the non-sialylated G0, G1, or G2 glycoforms, wherein said Fc-containing protein has enhanced affinity for FcγRIIA and FcγRIIIA, enhanced activity in NK cell-mediated ADCC assays, reduced affinity for FcγRI, reduced ability to activate macrophages, and prolonged serum half-life compared to the same Fc-containing therapeutic protein which is substantially in the G2S2 glycoform.

26. The protein of claim 25, wherein the protein is a recombinantly expressed monoclonal antibody modified enzymatically using sialyltransferases or sialidases.

27. The protein of claim 25, wherein the protein is a recombinantly expressed monoclonal antibody purified using one or more of affinity chromatography and ion-exchange chromatography.

28. The protein of claim 27, wherein the affinity chromatography is lectin affinity chromatography.

29. The protein of claim 27, wherein the protein is a monoclonal antibody expressed in a host cell genetically engineered to have enhanced levels of sialylated or asialylated oligosaccharides.

30. A method for preparing a batch of therapeutic recombinant Fc-containing protein characterized as comprising an immunoglobulin IgG isotype domain of at least a hinge region, a CH2, and a CH3 domain, wherein the method comprises treating the batch with an enzyme to add or remove sugar residues from the polysaccharide chains attached to said protein.

31. A pharmaceutical composition comprising a protein produced by the method of claim 30 in combination with a pharmaceutically acceptable carrier.

32. A method for treatment of a disease or condition selected from oncology-related disorders and disorders associated with inflammation, the method comprising administering to a subject having the disease or condition an effective dose of the protein produced by the method of claim 30.

33. The method of claim 32, wherein said disease or condition is rheumatoid arthritis or inflammatory bowel disease.

34. A method for controlling a binding affinity for a target of an Fc-containing molecule having a binding domain specific for the target, comprising altering the sialylation of the oligosaccharides in the Fc region.

35. The method of claim 34, wherein the sialylation is increased in the Fc region.

36. The method of claim 34, wherein the sialylation is decreased in the Fc region.

37. The method of claim 34, wherein the sialylation is altered from the wild type Fc region by at least one method selected from the group consisting of enzymatic treatment, enzymatic modification of the molecule, genetic manipulation of the molecule, lectin chromatography, affinity chromatography, ion exchange chromatography, changing the cell line used for expression of the protein, and culturing host cells used to produce the Fc-containing protein in serum.

38. The method of claim 37, wherein the enzymatic treatment comprises treating with sialidase or sialyltransferase.

39. The method of claim 34, wherein the target is an immobilized target.

40. The method of claim 39, wherein the target is expressed on the surface of a cell.

41. The method of claim 34, wherein the Fc-containing molecule is an antibody.

* * * * *